
Emma B. answered 04/12/22
Registered Nurse with 5 years experience, MSN in Nursing Education
ACE-inhibitor-induced angioedema is treated with corticosteroids, histamine 1 and 2 (H1 and H2) blockers, and/or intramuscular or subcutaneous epinephrine. However, there is no specific evidence supporting the use of these medications in the literature. While the kallikrein receptor blocker ecallantide and the bradykinin receptor antagonist icatibant have been approved by the FDA for the management of hereditary angioedema, there is not enough data available to support their use in ACEI-induced angioedema—only one randomized, controlled trial has been published for each agent.
A recent U.S. randomized clinical trial of icatibant showed that in participants with ACEI-induced angioedema, the medication led to a significantly faster resolution of edema compared with traditional treatment with corticosteroids and antihistamines. Another recent clinical trial in patients with ACEI-induced angioedema showed that the addition of ecallantide to standard therapy did not improve angioedema compared with placebo plus standard therapy. A successful reversal of life-threatening resistant angioedema with fresh-frozen plasma has been reported.
References
Temiño VM, Peebles RS Jr. The spectrum and treatment of angioedema. Am J Med. 2008;121(4):282-286.
Baş M, Greve J, Stelter K, et al. A randomized trial of icatibant in ACE-inhibitor-induced angioedema. N Engl J Med. 2015;372(5):418-425.
Rasmussen ER, Mey K, Bygum A. Angiotensin-converting enzyme inhibitor-induced angioedema—a dangerous new epidemic. Acta Derm Venereol. 2014;94(3):260-264.
Lewis LM, Graffeo C, Crosley P, et al. Ecallantide for the acute treatment of angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter, randomized, controlled trial. Ann Emerg Med. 2015; 65(2):204-213.